Literature DB >> 26637705

B-cell receptor pathway modulators in NHL.

Kristie A Blum1.   

Abstract

With the recent success of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, and the phosphoinositide-3-kinase (PI3K) inhibitor, idelalisib, in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), a number of new agents targeting the B-cell receptor (BCR) pathway are in clinical development. In addition, multiple trials combining these agents with conventional cytotoxic chemotherapy, immunomodulatory agents, monoclonal antibodies, or other kinase inhibitors are underway. This review will summarize the current data with the use of single agent and combination therapy with BCR inhibitors in NHL. In addition, commonly encountered as well as serious toxicities and hypothesized resistance mechanisms will be discussed. Lastly, this review will examine the future of these agents and opportunities to maneuver them into the front-line setting in selected NHL subtypes.
© 2015 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26637705      PMCID： PMC4871119          DOI： 10.1182/asheducation-2015.1.82

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  28 in total

1.  Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

2.  A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia.

Authors:  Irene M Ghobrial; Philippe Moreau; Brianna Harris; Tiffany Poon; Eric Jourdan; Hervé Maisonneuve; Karim A Benhadji; Anwar M Hossain; Tuan S Nguyen; James E Wooldridge; Veronique Leblond
Journal:  Clin Cancer Res       Date:  2012-08-09       Impact factor: 12.531

3.  Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

Authors:  Michael J Robertson; Brad S Kahl; Julie M Vose; Sven de Vos; Mary Laughlin; Patrick J Flynn; Kendrith Rowland; Jose C Cruz; Stuart L Goldberg; Luna Musib; Christelle Darstein; Nathan Enas; Jeffery L Kutok; Jon C Aster; Donna Neuberg; Kerry J Savage; Ann LaCasce; Donald Thornton; Christopher A Slapak; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2007-03-26       Impact factor: 44.544

4.  Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

Authors:  C Y Cheah; D Chihara; J E Romaguera; N H Fowler; J F Seymour; F B Hagemeister; R E Champlin; M L Wang
Journal:  Ann Oncol       Date:  2015-02-23       Impact factor: 32.976

Review 5.  Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.

Authors:  L Alinari; C Quinion; K A Blum
Journal:  Clin Pharmacol Ther       Date:  2015-01-20       Impact factor: 6.875

6.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

7.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Jonathan W Friedberg; Jeff Sharman; John Sweetenham; Patrick B Johnston; Julie M Vose; Ann Lacasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P Leonard; Larry D Cripe; Stephanie A Gregory; Michael P Sterba; Ann M Lowe; Ronald Levy; Margaret A Shipp
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

8.  A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Authors:  F Morschhauser; J F Seymour; H C Kluin-Nelemans; A Grigg; M Wolf; M Pfreundschuh; H Tilly; J Raemaekers; M B van 't Veer; N Milpied; G Cartron; A Pezzutto; A Spencer; F Reyes; M Dreyling
Journal:  Ann Oncol       Date:  2007-09-28       Impact factor: 32.976

9.  A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Authors:  Ian W Flinn; Nancy L Bartlett; Kristie A Blum; Kirit M Ardeshna; Ann S LaCasce; Christopher R Flowers; Andrei R Shustov; Kenneth S Thress; Patrick Mitchell; Fred Zheng; Jeffrey M Skolnik; Jonathan W Friedberg
Journal:  Eur J Cancer       Date:  2015-12-18       Impact factor: 9.162

Review 10.  Management of adverse events associated with idelalisib treatment: expert panel opinion.

Authors:  Steven E Coutré; Jacqueline C Barrientos; Jennifer R Brown; Sven de Vos; Richard R Furman; Michael J Keating; Daniel Li; Susan M O'Brien; John M Pagel; Martin H Poleski; Jeff P Sharman; Nai-Shun Yao; Andrew D Zelenetz
Journal:  Leuk Lymphoma       Date:  2015-05-19
View more
  6 in total

1.  Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2.

Authors:  Wenjun Wu; Weige Wang; Carrie A Franzen; Hui Guo; Jimmy Lee; Yan Li; Madina Sukhanova; Dong Sheng; Girish Venkataraman; Mei Ming; Pin Lu; Anhui Gao; Chunmei Xia; Jia Li; Liang Leo Zhang; Vivian Changying Jiang; Michael L Wang; Jorge Andrade; Xiaoyan Zhou; Y Lynn Wang
Journal:  Blood Adv       Date:  2021-01-12

2.  BCALM (AC099524.1) Is a Human B Lymphocyte-Specific Long Noncoding RNA That Modulates B Cell Receptor-Mediated Calcium Signaling.

Authors:  Sarah C Pyfrom; Chaz C Quinn; Hannah K Dorando; Hong Luo; Jacqueline E Payton
Journal:  J Immunol       Date:  2020-06-22       Impact factor: 5.422

Review 3.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31

Review 4.  Gene mutations and actionable genetic lesions in mantle cell lymphoma.

Authors:  Makhdum Ahmed; Leo Zhang; Krystle Nomie; Laura Lam; Michael Wang
Journal:  Oncotarget       Date:  2016-09-06

5.  A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib.

Authors:  Geoffrey Shouse; Miemie Thinn
Journal:  Case Rep Hematol       Date:  2018-03-13

Review 6.  Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?

Authors:  Annalisa Chiappella; Jennifer Crombie; Anna Guidetti; Umberto Vitolo; Philippe Armand; Paolo Corradini
Journal:  Hemasphere       Date:  2019-07-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.